Of course, in a few years the Renewal Technologies products are already approved. Big Pharma (BP) understands only to well that Renewal is not the serious threat that BIEL represents. For instance, Renewal's Laser Touch One device is priced at, $489.00. By contrast, BIEL's product is priced in the neighborhood of $30.00. Hence, that price gap which favors BIEL in a big way, presents a tremendous market disruption for BP. So, it's plausible that the FDA has gotten their marching orders from BP. Those orders may instruct, thus so: Give clearance to BIEL? NOT!
Nonetheless, Go BIEL!!!